Jakob Schlapbach will resign as CFO of Cytos Biotechnology

Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors

Schlieren (Zurich), Switzerland, March 22, 2010 - Cytos Biotechnology Ltd (SIX:CYTN) informs that Jakob Schlapbach (59) wishes to make use of the possibility of early retirement and plans to resign from his operational role as CFO of Cytos Biotechnology Ltd during the year 2010. To secure his further valuable support and long years of experience, Jakob Schlapbach will be proposed at the forthcoming annual general meeting for the election to the board of directors. A search for a new CFO has been initiated.

For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: [email protected]
Website: www.cytos.com
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products - the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a diversified pipeline of ImmunodrugTM candidates in various disease areas, of which six are currently in clinical development. The ImmunodrugTM candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 83 full-time employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.